Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice

International Journal of Molecular Sciences

Volumn 9, Issue 11, 2008, Pages 2253-2264

  Zhou, Xiaoxu ^a   Li, Dan ^a   Yan, Wei ^a   Li, Weimin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; IL 6; Pravastatin; SOCS3; STAT3

Indexed keywords

APOLIPOPROTEIN E; INTERLEUKIN 6; PRAVASTATIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

MUS;

EID: 56449105586     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms9112253     Document Type: Article

References (32)

1. Brasier, A.R.; Recinos, A. 3rd; Eledrisi, M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1257-1266.
2. Stenvinkel, P.; Heimbürger, O.; Jogestrand, T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity. Am. J. Kidney Dis. 2002, 39, 274-382.
3. Kato, A.; Odamaki, M.; Takita, T.; Maruyama, Y.; Kumagai, H.; Hishida, A. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 2002, 61, 1143-1152.
4. Taga, T.; Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15, 797-819.
5. Rose-John, S. Coordination of interleukin-6 biology by membrane bound and soluble receptors. Adv. Exp. Med. Biol. 2001, 495, 145-151.
6. Starr, R.; Willson, T.A.; Viney, E.M.; Murray, L.J.; Rayner, J.R.; Jenkins, B.J.; Gonda, T.J.; Alexander, W.S.; Metcalf, D.; Nicola, N.A.; Hilton, D.J. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387, 917-921.
7. Auernhammer, C.J.; Chesnokova, V.; Bousquet, C.; Melmed, S. Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol. Endocrinol. 1998, 12, 954-961.
8. Paffen, E.; DeMaat, M.P. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc. Res. 2006, 71, 30-39.
9. Verma, S.; Szmitko, P.E.; Ridker, P.M. C-reactive protein comes of age. Nat. Clin. Pract. Cardiovasc. Med. 2005, 2, 29-36.
10. Recinos, A. 3rd; LeJeune, W.S.; Sun, H.; Lee, C.Y.; Tieu, B.C.; Lu, M.; Hou, T.; Boldogh, I.; Tilton, R.G.; Brasier, A.R. Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis 2007, 194, 125-133.
11. Huang, K.C.; Chen, C.W.; Chen, J.C.; Lin, W.W. Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett. 2003, 555, 385-389.
12. Werner, N.; Nickenig, G.; Laufs, U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 2002, 97, 105-116.
13. Johnson, J.; Carson, K.; Williams, H.; Karanam, S.; Newby, A.; Angelini, G.; George, S.; Jackson, C. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005, 111, 1422-1430
14. Kleemann, R.; Princen, H.M.; Emeis, J.J.; Jukema, J.W.; Fontijn, R.D.; Horrevoets, A.J.; Kooistra, T.; Havekes, L.M. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: Evidence for antiinflammatory effects of rosuvastatin. Circulation 2003, 108, 1368-1374.
15. Liao, J.K.; Laufs, U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 89-118.
16. Wincewicz, A.; Sulkowska, M.; Rutkowski, R.; Sulkowski, S.; Musiatowicz, B.; Hirnle T.; Famulski, W.; Koda, M.; Sokol, G.; Szarejko, P. STAT1 and STAT3 as intracellular regulators of vascular remodeling. Eur. J. Intern. Med. 2007, 18, 267-271.
17. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole T.G.; Brown L.; Warnica J.W.; Arnold J.M.; Wun C.C.; Davis B.R.; Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996, 335, 1001-1009.
18. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996, 348, 1339-1342.
19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998, 339, 1349-1357.
20. Bea, F.; Blessing, E.; Bennett, B.; Levitz, M.; Wallace, E.P.; Rosenfeld, M.E. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc. Biol. 2002, 22, 1832-1837.
21. Johnson, J.; Carson, K.; Williams, H.; Karanam, S.; Newby, A.; Angelini, G.; George, S.; Jackson, C. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: Model characterization and effects of pravastatin treatment. Circulation. 2005, 111, 1422-1430.
22. Tedgui, A.; Mallat, Z. Cytokines in atherosclerosis: pathogenic and regulatorypathways. Physiol. Rev. 2006, 86, 515-581.
23. Ito, T.; Ikeda, U.; Shimpo, M.; Ohki, R.; Takahashi, M.; Yamamoto, K.; Shimada, K. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc. Drugs Ther. 2002, 16, 121-126.
24. Dronadula, N.; Liu, Z.; Wang, C.; Cao, H.; Rao, G.N. STAT-3-dependent cytosolic phospholipase A2 expression is required for thrombin-induced vascular smooth muscle cell motility. J. Biol. Chem. 2005, 280, 3112-3120.
25. Dauer, D.J.; Ferraro, B.; Song, L.; Yu, B.; Mora, L.; Buettner, R.; Enkemann, S.; Jove, R.; Haura, E.B. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24, 3397-3408.
26. Arnaud, C.; Burger, F.; Steffens, S.; Veillard, NR.; Nguyen, T.H.; Trono, D.; Mach, F. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1231-1236.
27. Naka, T.; Narazaki, M.; Hirata, M, Matsumoto, T.; Minamoto, S.; Aono, A.; Nishimoto, N.; Kajita, T.; Taga, T.; Yoshizaki, K.; Akira, S.; Kishimoto, T. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387, 924-929
28. Niemand, C.; Nimmesgern, A.; Haan, S.; Fischer, P.; Schaper, F.; Rossaint, R.; Heinrich, P.C.; Müller-Newen, G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 2003, 170, 3263-3272.
29. Shouda, T.; Yoshida, T.; Hanada, T.; Wakioka, T.; Oishi, M.; Miyoshi, K.; Komiya, S.; Kosai, K.; Hanakawa, Y.; Hashimoto, K.; Nagata, K.; Yoshimura, A. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 2001, 108, 1781-1788.
30. Mulhaupt, F.; Matter, C.M.; Kwak, B.R.; Pelli, G.; Veillard, N.R.; Burger, F.; Graber, P.; Lüscher, T.F.; Mach, F. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 2003, 59, 755-766.
31. Zadelaar, S.; Kleemann, R.; Verschuren, L.; de Vries-Van der Weij, J.; van der Hoorn, J.; Princen, H.M.; Kooistra, T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1706-1721.
32. Hong, F.; Jaruga, B.; Kim, W.H.; Radaeva, S.; El-Assal, O.N.; Tian, Z.; Nguyen, V.A.; Gao, B. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J. Clin. Invest. 2002, 110, 1503-1513.